Editas Medicine Statistics
Share Statistics
Editas Medicine has 82.55M shares outstanding. The number of shares has increased by 1.03% in one year.
| Shares Outstanding | 82.55M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.29% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 81.78M |
| Failed to Deliver (FTD) Shares | 23 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 17.24M, so 20.88% of the outstanding shares have been sold short.
| Short Interest | 17.24M |
| Short % of Shares Out | 20.88% |
| Short % of Float | 21.08% |
| Short Ratio (days to cover) | 8.76 |
Valuation Ratios
The PE ratio is -5.02 and the forward PE ratio is -1.31.
| PE Ratio | -5.02 |
| Forward PE | -1.31 |
| PS Ratio | 9.85 |
| Forward PS | 6.4 |
| PB Ratio | 2.2 |
| P/FCF Ratio | -5.62 |
| PEG Ratio | n/a |
Enterprise Valuation
Editas Medicine Inc. has an Enterprise Value (EV) of 682.42M.
| EV / Earnings | -4.45 |
| EV / Sales | 8.74 |
| EV / EBITDA | -4.18 |
| EV / EBIT | -4.03 |
| EV / FCF | -4.98 |
Financial Position
The company has a current ratio of 5.39, with a Debt / Equity ratio of 0.03.
| Current Ratio | 5.39 |
| Quick Ratio | 5.39 |
| Debt / Equity | 0.03 |
| Total Debt / Capitalization | 3.37 |
| Cash Flow / Debt | -10.87 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.44% and return on capital (ROIC) is -43.87%.
| Return on Equity (ROE) | -0.44% |
| Return on Assets (ROA) | -0.31% |
| Return on Capital (ROIC) | -43.87% |
| Revenue Per Employee | 294.80K |
| Profits Per Employee | -578.18K |
| Employee Count | 265 |
| Asset Turnover | 0.16 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -86.83% in the last 52 weeks. The beta is 2.01, so Editas Medicine 's price volatility has been higher than the market average.
| Beta | 2.01 |
| 52-Week Price Change | -86.83% |
| 50-Day Moving Average | 2.82 |
| 200-Day Moving Average | 4.79 |
| Relative Strength Index (RSI) | 31.38 |
| Average Volume (20 Days) | 2.30M |
Income Statement
In the last 12 months, Editas Medicine had revenue of $78.12M and earned -$153.22M in profits. Earnings per share was $-2.02.
| Revenue | 78.12M |
| Gross Profit | -99.53M |
| Operating Income | -169.18M |
| Net Income | -153.22M |
| EBITDA | -163.12M |
| EBIT | -169.18M |
| Earnings Per Share (EPS) | -2.02 |
Balance Sheet
The company has $123.65M in cash and $36.54M in debt, giving a net cash position of $87.12M.
| Cash & Cash Equivalents | 123.65M |
| Total Debt | 36.54M |
| Net Cash | 87.12M |
| Retained Earnings | -1.23B |
| Total Assets | 327.57M |
| Working Capital | 198.79M |
Cash Flow
In the last 12 months, operating cash flow was -$132.18M and capital expenditures -$4.72M, giving a free cash flow of -$136.90M.
| Operating Cash Flow | -132.18M |
| Capital Expenditures | -4.72M |
| Free Cash Flow | -136.90M |
| FCF Per Share | -1.8 |
Margins
Gross margin is -127.4%, with operating and profit margins of -216.56% and -196.13%.
| Gross Margin | -127.4% |
| Operating Margin | -216.56% |
| Pretax Margin | -196.13% |
| Profit Margin | -196.13% |
| EBITDA Margin | -208.8% |
| EBIT Margin | -216.56% |
| FCF Margin | -175.23% |
Dividends & Yields
EDIT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -140.28% |
| FCF Yield | -115.17% |
Analyst Forecast
The average price target for EDIT is $8, which is 455.6% higher than the current price. The consensus rating is "Hold".
| Price Target | $8 |
| Price Target Difference | 455.6% |
| Analyst Consensus | Hold |
| Analyst Count | 14 |
Scores
| Altman Z-Score | -6.82 |
| Piotroski F-Score | 2 |